KDR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It’s the GeneMedi’s summary page for Target/Biomarker Introduction of KDR. The page also collects GeneMedi’s different modalities and formats products for KDR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the KDR target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]

Target ID

GM-T80975

Target Name

KDR

Gene ID

3791

Gene Official Name

KDR

Gene Alias

CD309, FLK1, VEGFR, VEGFR2

Protein Sub-location

Transmembrane Protein

Category

Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine

Pre-made KDR-specific INN-index biosimilar (antibody&conjugates)-Vulinacimab, Olinvacimab, Ramucirumab, Pulocimab, alacizumab pegol, pegdinetanib, Alacizumab, Tanibirumab

Anti-KDR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Filters Sort results
Reset Apply
Cat No.
Products Name (INN Index)
INN Name
Previous Name
Target
Format
Order
Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
Alacizumab
NA
KDR
di-Fab
Pre-Made Olinvacimab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
Olinvacimab
Tanibirumab
KDR
Whole mAb
Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
Ramucirumab
NA
KDR
Whole mAb
Pre-Made Tanibirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
Tanibirumab
olinvacimab
KDR
Whole mAb
Pre-Made Vulinacimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody
Vulinacimab
NA
VEGFR2
Whole mAb
Pre-Made Pulocimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody
Pulocimab
NA
VEGFR2
Whole mAb

Anti-VGFR2/ KDR/ CD309 antibody for FACS & in-vivo assay| GMab

Pre-made anti-KDR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-KDR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Filters Sort results
Reset Apply
Cat No.
Antibody Name
Format
Classified by tag
Order
Anti-KDR monoclonal antibody
mab
FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody